Cost-effectiveness of apixaban versus other oral anticoagulants and aspirin for stroke prevention in atrial fibrillation in indian subcontinent

被引：1
|
作者：
Kulkarni, N. [1 ]
Taur, S. [1 ]
Tichy, E. [2 ]
Kongnakorn, T. [3 ]
Sharma, R. [4 ]
机构：
[1] Pfizer India, Med Affairs, Mumbai, Maharashtra, India
[2] Evidera, Budapest, Hungary
[3] Evidera, London, England
[4] Fortis Hosp, Mohali, India
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷
关键词：
D O I：
10.1093/eurheartj/ehab849.022
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
    Lip, Gregory Y. H.
    Kongnakorn, Thitima
    Phatak, Hemant
    Kuznik, Andreas
    Lanitiss, Tereza
    Liu, Larry Z.
    Iloeje, Uchenna
    Hernandez, Luis
    Dorian, Paul
    [J]. CLINICAL THERAPEUTICS, 2014, 36 (02) : 192 - 210
  • [2] COST-EFFECTIVENESS OF APIXABAN VERSUS OTHER NEW ORAL ANTICOAGULANTS AND WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN VENEZUELA
    Fernandez Avila, Y.
    Garcia, K. C.
    Garrido Lecca, S.
    Donato, B. M.
    Juarez-Garcia, A.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A829 - A829
  • [3] COST-EFFECTIVENESS OF APIXABAN VERSUS OTHER NEW ORAL ANTICOAGULANTS FOR THE PREVENTION OF STROKE: AN ANALYSIS OF PATIENTS WITH ATRIAL FIBRILLATION IN GREECE
    Athanasakis, K.
    Arzoumanidou, D.
    Karampli, E.
    Armelidou, E.
    Giovas, P.
    Petrikkou, E.
    Kyriopoulos, J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A525 - A525
  • [4] Cost-effectiveness of apixaban against other novel oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation patients
    Lip, G. H. Y.
    Kongnakorn, T.
    Phatak, H.
    Kuznik, A.
    Rublee, D.
    Lanitis, T.
    Liu, L.
    Iloeje, U.
    Dorian, P.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 : 54 - 54
  • [5] COST-EFFECTIVENESS OF APIXABAN COMPARED TO ASPIRIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Lee, Soyon
    Anglade, Moise
    Hagstrom, Kelly
    Meng, Joy
    Kluger, Jeffrey
    Coleman, Craig
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E596 - E596
  • [6] Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
    Lanitis, Tereza
    Kongnakorn, Thitima
    Jacobson, Lena
    De Geer, Anna
    [J]. THROMBOSIS RESEARCH, 2014, 134 (02) : 278 - 287
  • [7] Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients
    Walter, Evelyn
    Voit, Marco
    Eichhober, Gerald
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (02) : 265 - 275
  • [8] Cost-effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
    Pradelli, Lorenzo
    Calandriello, Mario
    Di Virgilio, Roberto
    Bellone, Marco
    Tubaro, Marco
    [J]. FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2014, 15 (04) : 101 - 112
  • [9] Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation
    Kansal, Anuraag R.
    Zheng, Ying
    Pokora, Tiffany
    Sorensen, Sonja V.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (02) : 225 - 237
  • [10] Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
    Oyaguez, Itziar
    Suarez, Carmen
    Luis Lopez-Sendon, Jose
    Ramon Gonzalez-Juanatey, Jose
    de Andres-Nogales, Fernando
    Suarez, Jorge
    Polanco, Carlos
    Soto, Javier
    [J]. PHARMACOECONOMICS-OPEN, 2020, 4 (03) : 485 - 497
12345